menu
    • menu
    [{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Niacinamide","moa":"ADP-ribosyl cyclase\/cyclic ADP-ribose hydrolase 2|Exotoxin A; Poly [ADP-ribose] polymerase 1| NAD-dependent protein deacylase sirtuin-5, mitochondrial| L-lactate dehydrogenase A chain","graph1":"Nephrology","graph2":"Phase I","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beth Israel Deaconess Medical Center \/ Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases","highestDevelopmentStatusID":"6","companyTruncated":"Beth Israel Deaconess Medical Center \/ Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases"},{"orgOrder":0,"company":"Shenzhen Precision Health Food Technology Co. Ltd.,","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Shenzhen Precision Health Food Technology Co. Ltd.,","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Shenzhen Precision Health Food Technology Co. Ltd., \/ Undisclosed"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Acquisition","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Anglo-French Drugs and industries \/ Lupin Ltd"},{"orgOrder":0,"company":"MEDICE Health Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Nephrology","graph2":"Phase II","graph3":"MEDICE Health Family","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MEDICE Health Family \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MEDICE Health Family \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Schleswig-Holstein","sponsor":"Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"University Hospital Schleswig-Holstein","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Schleswig-Holstein \/ Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research","highestDevelopmentStatusID":"9","companyTruncated":"University Hospital Schleswig-Holstein \/ Ced Service | Gesellschaft f\u00fcr Therapieforschung mbH | German Federal Ministry of Education and Research"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"EpiDestiny","sponsor":"National Institutes of Health | National Heart, Lung, and Blood Institute","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Poly [ADP-ribose] polymerase 1 (PARP1)","graph1":"Genetic Disease","graph2":"Phase I","graph3":"EpiDestiny","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EpiDestiny \/ National Institutes of Health | National Heart, Lung, and Blood Institute","highestDevelopmentStatusID":"6","companyTruncated":"EpiDestiny \/ National Institutes of Health | National Heart, Lung, and Blood Institute"},{"orgOrder":0,"company":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara","sponsor":"OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Niacinamide","moa":"PARP1","graph1":"Ophthalmology","graph2":"Undisclosed","graph3":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara \/ OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa","highestDevelopmentStatusID":"1","companyTruncated":"Universit\u00e0 degli Studi 'G. d'Annunzio' Chieti e Pescara \/ OFFHEALTH S.p.A. | Universit\u00e0 degli Studi di Sassari | University of Pisa"},{"orgOrder":0,"company":"Duta Wacana Christian University","sponsor":"PT SOHO Global Health Tbk","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDONESIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Duta Wacana Christian University","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duta Wacana Christian University \/ PT SOHO Global Health Tbk","highestDevelopmentStatusID":"9","companyTruncated":"Duta Wacana Christian University \/ PT SOHO Global Health Tbk"},{"orgOrder":0,"company":"S.LAB (SOLOWAYS)","sponsor":"Triangel Scientific | Center of New Medical Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"RUSSIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"S.LAB (SOLOWAYS)","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S.LAB (SOLOWAYS) \/ Triangel Scientific | Center of New Medical Technologies","highestDevelopmentStatusID":"1","companyTruncated":"S.LAB (SOLOWAYS) \/ Triangel Scientific | Center of New Medical Technologies"},{"orgOrder":0,"company":"Nestle Health Sciences SA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWITZERLAND","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Nestle Health Sciences SA","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nestle Health Sciences SA \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Nestle Health Sciences SA \/ Undisclosed"},{"orgOrder":0,"company":"Standard Process Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Niacinamide","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Standard Process Inc.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Standard Process Inc. \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Standard Process Inc. \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Nicotinamide

    Menu

    Nicotinamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Università degli Studi 'G. d'Annunzio' Chieti e Pescara

                            Country arrow
                            AES
                            Not Confirmed

                            Università degli Studi 'G. d'Annunzio' Chieti e Pescara

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Undisclosed

                            Sponsor : OFFHEALTH S.p.A. | Università degli Studi di Sassari | University of Pisa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nicotinamide Levels & mtDAMP/SASP Correlation In Glaucoma Patients

                            Details : Nicotinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Glaucoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 05, 2025

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Undisclosed

                            Sponsor : OFFHEALTH S.p.A. | Università degli Studi di Sassari | University of Pisa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Beth Israel Deaconess Medical Center

                            U.S.A arrow
                            AES
                            Not Confirmed

                            Beth Israel Deaconess Medical Center

                            U.S.A arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response

                            Details : Niacinamide is a Other Small Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Kidney Diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 21, 2025

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Boston University Charles River Campus | National Institute of Diabetes and Digestive and Kidney Diseases

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            University Hospital Schleswig-Holstein

                            Country arrow
                            AES
                            Not Confirmed

                            University Hospital Schleswig-Holstein

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Immunology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Ced Service | Gesellschaft für Therapieforschung mbH | German Federal Ministry of Education and Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Oral Controlled-Ileocolonic-Release Nicotinamide (CICR-NAM) in Patients with Mild to Mo...

                            Details : CICR-NAM (Nicotinamide) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Colitis, Ulcerative.

                            Product Name : CICR-NAM

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 05, 2024

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Ced Service | Gesellschaft für Therapieforschung mbH | German Federal Ministry of Education and Research

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            S.LAB (SOLOWAYS)

                            Country arrow
                            AES
                            Not Confirmed

                            S.LAB (SOLOWAYS)

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Triangel Scientific | Center of New Medical Technologies

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluating the Impact of B Vitamin Supplementation (Solowaysâ„¢) on Homocysteine and LDL-C Levels in Patie...

                            Details : Vitamin B is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Hyperhomocysteinemia.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            December 08, 2023

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Triangel Scientific | Center of New Medical Technologies

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Standard Process Inc.

                            Country arrow
                            AES
                            Not Confirmed

                            Standard Process Inc.

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Standard Process Heart and Gut Health Study

                            Details : Vitamin B is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            April 03, 2023

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AES
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of 4 Weeks Supplementation of a Combination of Vitamin Bs and Taurine on Mental Performance in Healthy ...

                            Details : Vitamin B is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            February 17, 2023

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Shenzhen Precision Health Food Technology Co. Ltd.,

                            Country arrow
                            AES
                            Not Confirmed

                            Shenzhen Precision Health Food Technology Co. Ltd.,

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Improved Skin Whitening Outcomes Associated With Nicotinamide Fortified Consumption in 30 to 50- Year-old Wome...

                            Details : Nicotinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 25, 2023

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AES
                            Not Confirmed

                            Nestle Health Sciences SA

                            Switzerland arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults

                            Details : Nicotinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 26, 2022

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Anglo-French Drugs and industries

                            India arrow
                            AES
                            Not Confirmed

                            Anglo-French Drugs and industries

                            India arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Lupin Completes Acquisition of Brands from Anglo-French

                            Details : The acquisition will strengthen Lupin’s business by adding a portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical ...

                            Product Name : Beplex Forte

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Approved FDF

                            Sponsor : Lupin Ltd

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Duta Wacana Christian University

                            Country arrow
                            AES
                            Not Confirmed

                            Duta Wacana Christian University

                            Country arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Neurology

                            Study Phase : Phase II/ Phase III

                            Sponsor : PT SOHO Global Health Tbk

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Benefits of Vitamin B Combination as Add on Therapy in the Management of Painful Diabetic Neuropathy Patie...

                            Details : Vitamin B is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Diabetic Neuropathies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            December 30, 2020

                            Lead Product(s) : Niacinamide

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : PT SOHO Global Health Tbk

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth